Cargando…

Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study

BACKGROUND/AIMS: Renal complications related to BCR-ABL1-negative myeloproliferative neoplasms (MPNs) have not been examined fully in Asian populations. METHODS: We analyzed estimated glomerular filtration rate (eGFR) and its changes with time retrospectively in patients with BCR-ABL1-negative MPN f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baek, Seung-Woo, Moon, Ji Young, Ryu, Hyewon, Choi, Yoon-Seok, Song, Ik-Chan, Lee, Hyo-Jin, Yun, Hwan-Jung, Kim, Samyoung, Jo, Deog-Yeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030405/ https://www.ncbi.nlm.nih.gov/pubmed/28298076 http://dx.doi.org/10.3904/kjim.2016.263

Ejemplares similares

Acquired von willebrand syndrome in patients with Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2023)

Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms
por: Lee, Myung-Won, et al.
Publicado: (2022)

Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2022)

Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
por: Barcelos, Michelle Maccarini, et al.
Publicado: (2011)

GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms
por: Yang, Naery, et al.
Publicado: (2018)

Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia- negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2021)

Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients
por: Lee, Myeong-Won, et al.
Publicado: (2020)

BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
por: Mroczkowska-Bękarciak, Aleksandra, et al.
Publicado: (2023)

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms
por: Belliere, Julie, et al.
Publicado: (2020)

The immune landscape in BCR‐ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
por: Strickland, Marie, et al.
Publicado: (2021)

Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms
por: Morishita, Soji, et al.
Publicado: (2023)

PB2212: ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
por: Lee, Myung-Won, et al.
Publicado: (2023)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
por: Cassinat, Bruno, et al.
Publicado: (2020)

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
por: Beitzen-Heineke, Antonia, et al.
Publicado: (2021)

Recent advances in the bcr-abl negative chronic myeloproliferative diseases
por: Bennett, Michael, et al.
Publicado: (2006)

Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms
por: Lin, Xiaolan, et al.
Publicado: (2020)

Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm
por: Allegra, Alessandro, et al.
Publicado: (2020)

Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
por: Abbou, Norman, et al.
Publicado: (2022)

Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
por: Kim, Jinyong, et al.
Publicado: (2021)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

Mutational Analysis of SH2B3 in Korean Patients With BCR-ABL1 Negative Myeloproliferative Neoplasm
por: Kim, Namhee, et al.
Publicado: (2016)

Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India
por: Maddali, Madhavi, et al.
Publicado: (2021)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
por: Porto-Soares, Moysés Antonio, et al.
Publicado: (2020)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

P1053: NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Cvetkovic, Mirjana, et al.
Publicado: (2023)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
por: La Spina, Enrico, et al.
Publicado: (2023)

Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α
por: Aruna,, et al.
Publicado: (2018)

JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East
por: Safavi, Moeinadin, et al.
Publicado: (2021)

The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
por: Chia, Yuh Cai, et al.
Publicado: (2021)

PB2191: A RETROSPECTIVE MULTI-CENTER STUDY ON DIRECT ORAL ANTICOAGULANT USE IN BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Baysal, Mehmet, et al.
Publicado: (2023)

Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria
por: Song, Ik-Chan, et al.
Publicado: (2019)

Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study
por: Dambrauskienė, R, et al.
Publicado: (2017)

PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES
por: Altunok, Oguz, et al.
Publicado: (2023)

Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm
por: Kim, Namhee, et al.
Publicado: (2015)

Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms
por: Didone, Alline, et al.
Publicado: (2015)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
por: Cattaneo, Daniele, et al.
Publicado: (2021)

Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms
por: Ding, Li, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8qsur8qmvf265p7pnvhp27rmct